Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus Calmette-Guerin therapy

Takanori Murakami, Shin Ebara, Takashi Saika, Shin Irie, Katsuji Takeda, Yoshio Maki, Sadayuki Miyaji, Daisuke Manabe, Haruki Kaku, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

We evaluated the need for transurethral biopsy at first follow-up after intravesical bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Pathological results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of positive bladder biopsy results. Fifty-three of 54 patients (98.1%) with no visible recurrent tumor and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystos-copy and negative urinary cytology. Copyright

Original languageEnglish
Pages (from-to)341-344
Number of pages4
JournalActa medica Okayama
Volume61
Issue number6
Publication statusPublished - Dec 1 2007

Keywords

  • BCG therapy
  • Bladder cancer
  • Cystoscopy
  • Transurethral biopsy
  • Urinary cytology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus Calmette-Guerin therapy'. Together they form a unique fingerprint.

Cite this